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Respiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract infections in infants and elderly indi-
viduals. Its fusion (F) protein is critical for virus infection. It is targeted by several investigational antivirals and by palivizumab,
a humanized monoclonal antibody used prophylactically in infants considered at high risk of severe RSV disease. ALX-0171 is a
trimeric Nanobody that binds the antigenic site II of RSV F protein with subnanomolar affinity. ALX-0171 demonstrated in
vitro neutralization superior to that of palivizumab against prototypic RSV subtype A and B strains. Moreover, ALX-0171 com-
pletely blocked replication to below the limit of detection for 87% of the viruses tested, whereas palivizumab did so for 18% of
the viruses tested at a fixed concentration. Importantly, ALX-0171 was highly effective in reducing both nasal and lung RSV ti-
ters when delivered prophylactically or therapeutically directly to the lungs of cotton rats. ALX-0171 represents a potent novel
antiviral compound with significant potential to treat RSV-mediated disease.
Human respiratory syncytial virus (RSV) is themost importantviral pathogen causing acute lower respiratory tract infec-
tions in infants worldwide and is estimated to result in3.4 mil-
lion yearly hospitalizations and200,000 deaths globally (1). RSV
typically causes its primary infection at the point of entry: apical
ciliated epithelial cells that line the nasal cavity and airways (2, 3).
Primary infections are usually symptomatic, with clinical signs
ranging from mild upper respiratory tract illness to severe lower
respiratory tract infections, including pneumonia and bronchioli-
tis (4). In addition to the acute consequences of infection, the
development of long-term recurrent wheezing and asthma has
been associated with severe RSV infections in infancy (5, 6). De-
spite the major clinical importance of RSV, no vaccines or widely
accepted antiviral therapies are currently available. The only avail-
able drug specific for humanRSV is palivizumab (Synagis), amar-
keted monoclonal antibody that is administered prophylactically
before and during the RSV season to infants at high risk of having
severe human RSV disease (7–9). Its use is restricted to premature
infants (gestational age,29 weeks), if they have no other under-
lying morbidities, and infants with chronic lung disease, congen-
ital heart disease, or a compromised immune system during the
first year of life (10).
RSV is a member of the Pneumovirus genus of the Paramyxo-
viridae family and has a linear single-stranded, nonsegmented
RNA molecule of negative polarity as its genome. This genome
contains 10 genes which encode 11 proteins. The transmembrane
glycoproteins F and G are the primary surface antigens of RSV.
The attachment (G) protein mediates binding to cell receptors,
while the F protein promotes fusion of the viral and cell mem-
branes, allowing virus entry into the host cell cytoplasm (11). The
F protein also promotes the fusion of infected cells with adjacent
uninfected cells, facilitating the formation of multinucleated cell
formations (syncytia), which allow cell-to-cell transmission of the
replicated viral RNAand confer additional protection for the virus
against host immune responses (12).
On the basis of the antigenic and genetic variability of the G
protein, two subgroups of RSV (subgroups A [RSV-A] and B
[RSV-B]) have been identified, and these are composed of evolv-
ing genotypes (13–17). In contrast to the G protein, the F protein
is mostly conserved between RSV subgroups A and B (89% amino
acid identity) and is therefore considered the most promising tar-
get for the development of viral entry inhibitors.
Nanobodies are therapeutic proteins derived from the heavy-
chain variable domains (VHH) that occur naturally in heavy
chain-only immunoglobulins of the Camelidae (18, 19). The for-
matting flexibility of Nanobodies into multivalent constructs,
their small size, their stability (which allows delivery through neb-
ulization), and their ease of production make their use against
viral targets appealing (20–22).
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Here we describe the in vitro and in vivo characterization of
ALX-0171, a trivalent Nanobody composed of three monovalent
Nb017 moieties linked together with glycine-serine (GS) linkers
which is designed to target the RSV F protein for delivery via
inhalation. ALX-0171 is currently in clinical development for the
treatment of RSV infections in infants (23).
MATERIALS AND METHODS
Generation of RSV-specific Nanobodies. Monovalent RSV F protein-
specific Nanobodies were identified from immune libraries of llamas that
received repetitive injections with soluble recombinant F protein
(FTM-NN protein), inactivated RSV-A (catalog number 8RSV79;
HyTest), or a combination of both antigens. The soluble recombinant
form of the F protein (derived from the Long strain) was produced with
recombinant Sendai virus in embryonated eggs (24). RSV-neutralizing
Nanobodies were identified by screening 162 distinct clones in an in vitro
microneutralization assay with RSV subtype A Long onHEp-2 cells. RSV-
neutralizing Nanobodies were formatted into multivalent constructs by
genetic fusionwith flexibleGly-Ser (GS) linkers of different lengths.Mon-
ovalent RSV Nanobody was routinely generated as C-terminal c-myc-
His-tagged proteins in Escherichia coli (22). For the production of un-
tagged monovalent and trivalent Nanobody constructs, a Pichia pastoris
X-33 expression system was used (see Fig. S1 in the supplemental mate-
rial). ALX-0171 is a trimeric Nanobody consisting of three RSV-targeting
Nb017 subunits linked by two GS linkers.
Competition enzyme-linked immunosorbent assay (ELISA). Nine-
ty-six-well microtiter plates (MaxiSorp immunoplates; Nunc) were
coated overnight with inactivated RSV-A (HyTest) at 3.5 g/ml in bicar-
bonate buffer. The plateswere blocked for 1 hwith SuperBlockT20 (phos-
phate-buffered saline [PBS]) blocking buffer (Pierce) before being
washed 3 times with PBS–0.05% Tween 20. Dilutions of ALX-0171 or
palivizumab were mixed with 10 nM biotinylated ALX-0171 (1:1 ratio)
and immediately transferred to the plates. After overnight incubation at
room temperature (RT) and appropriate washing, a 1/3,000 dilution of
peroxidase-labeled streptavidin (Thermo Scientific) was added to the
plates for 1 h at RT. Bound streptavidin-horseradish peroxidase was re-
vealed by adding 100 l/well of enhanced soluble tetramethylbenzidine
(esTMB; SDTReagents) for 10min, followed by 1NHCl. The absorbance
was read at 450 nm, and the reference wavelength was 620 nm.
SPR.Affinity constants (the equilibriumdissociation constants [KDs])
of Nb017, ALX-0171, and palivizumab were determined by surface plas-
mon resonance (SPR) analysis on a Biacore X100 instrument (GEHealth-
care). Fab fragments of antigenic site Ø-specific human monoclonal an-
tibody (MAb) D25 (Fab D25) (25, 26) and antigenic site I-specific mouse
MAb2F (Fab 2F) (27)were used as controls. In brief, anti-Hismonoclonal
antibody (GE Healthcare) was amine coupled to a CM5 sensor chip at a
density of 12,000 to 13,000 resonance units (RU) in 10mMacetate buffer,
pH 4.5. Approximately 70 RU of His-tagged prefusion F protein was then
bound to the anti-His monoclonal antibody. Compounds (ALX-0171,
Nb017, Fab D25, Fab 2F, and palivizumab) were injected at 5 different
concentrations (1 to 16 nM for ALX-0171, 8 to 128 nM for Nb017, 4 to 64
nM for palivizumab, 1.25 to 20 nM for Fab 2F and Fab D25) at a flow rate
of 30 l/min. The association and dissociation phases were 2 and 13 min,
respectively (for Fab D25, the dissociation time was increased to 30 min).
The chip was regenerated using 10mMglycine, pH 1.5. Different concen-
trations of the compounds were used to generate binding curves, which
were fitted to a 1:1 Langmuir binding model for the calculation of the
kinetic parameters association rate (kon) and dissociation rate (koff). The
KD was then calculated as the ratio of these two rate constants (koff/kon).
Binding ofNanobodies to RSV escapemutant F protein.HEp-2 cells
grown in 100-mm-diameter plates were infected with either wild-type
RSV (the RSV Long strain) or previously described mutant viruses resis-
tant to neutralization by monoclonal antibodies (11, 28, 29) (multiplicity
of infection, 1 to 3 PFU/cell). After 48 h, the cells were harvested and
extractsweremade in 500l buffer/plate (the bufferwas 10mMTris-HCl,
pH 7.5, 150 mM NaCl, 5 mM EDTA, and 1% octyl-glucoside). Equal
amounts of each extract (50 l of a 1:500 dilution in PBS) were used to
coat 96-well microtiter plates overnight at 4°C. The wells were saturated
with 1% bovine serum albumin in PBS for 1 h, and after washing with
PBS, Nanobodies were added to the wells and the plates were incubated
for 1 h at RT. After washing, boundNanobodywas detectedwith a 1:1,000
dilution of rabbit anti-llama IgG antibody, followed by a 1:200 dilution of
peroxidase-conjugated donkey anti-rabbit polyclonal antibody. o-Phen-
ylenediamine dihydrochloride (OPD; Sigma) was used as the substrate,
and reactions were stoppedwith 3NH2SO4, after which the absorbance at
490 nm was measured.
RSV clinical strains. Original clinical isolates of RSV-A and RSV-B
strains were selected from the RSV bank at the Baylor College ofMedicine
(Houston, TX). Three additional RSV-A isolates (BT2a, BT3a, BT4a)were
isolated from infants hospitalized with bronchiolitis in the Royal Belfast
Hospital for Sick Children. This study was approved by The Office for
Research Ethics Committees Northern Ireland (ORECNI). Written in-
formedparental consentwas obtained. Theywere all isolated and cultured
in HEp-2 cells, as previously described (30, 31).
Antiviral assays. The neutralization activity of the selected Nanobod-
ies and palivizumab was measured in a microneutralization assay, a neu-
tralization assay, and a plaque reduction assay. They were performed us-
ing HEp-2 cell monolayers, as described in the supplemental material.
Cotton rat studies.Male and female cotton rats were bred and housed
in the Baylor College ofMedicine’s vivarium in cages covered with barrier
filters and given food and water ad libitum. Cotton rats weighing between
60 to 125 g were lightly anesthetized with isoflurane and intranasally chal-
lenged with 100l of 1.41 105 to 3.5 105 PFU of RSV Tracy, depend-
ing on the experiment. RSV Tracy stocks were grown in HEp-2 cells. All
the experimental protocols were approved by the Baylor College of Med-
icine Investigational Animal Care and Use Committee.
ALX-0171was administered either intranasally or by nebulization. For
intranasal administration, cotton rats were lightly anesthetized with iso-
flurane and inoculated intranasally with 100 l of ALX-0171.
For nebulization, an Akita2 Apixneb nebulizer (Vectura GmbH, Ger-
many) was used for whole-body exposure (see Fig. S2 in the supplemental
material).
Cotton rats were euthanized with CO2 at 4 days postinfection. The
large left lobe and one of the large right lobes of the lungs were removed,
rinsed in sterile water, and weighed. The left lobe was then transpleurally
lavaged using 3 ml of Iscove’s medium with 15% glycerol mixed with 2%
fetal bovine serum (FBS)–minimal essential medium (MEM) (1:1, vol/
vol) in a 3-ml syringe with a 26-gauge by 3/8-in. needle and injected at
multiple sites to totally inflate the lobe. Subsequently, the lavage fluid was
recovered by gently pressing the inflated lobe flat and further used to
transpleurally lavage the right lobe following the same technique. The
lavage fluid was collected and stored on ice until titrated. To obtain nasal
washes, the jaws were disarticulated, the head was removed, and 1 ml of
Iscove’s medium with 15% glycerol mixed with 2% FBS–MEM (1:1, vol/
vol) was pushed through each nare (total, 2ml). The effluentwas collected
from the posterior opening of the pallet and stored on ice until titrated.
RSV Tracy lung lavage titers and nasal wash titers were determined by
plaque assay as described in the supplemental material.
Statistical analysis. A one-way analysis of variance (ANOVA) fol-
lowed by a post hocDunnett’s test for pairwise comparisonwas performed
to compare the treated groups and the buffer-treated groups. A P value of
0.05 was considered statistically significant. Statistical analysis was per-
formed with GraphPad Prism (version 5) software.
RESULTS
Generation and production of ALX-0171. The development of a
Pichia pastoris strain for the production of ALX-0171 delivered a
stable recombinant strain suitable for themanufacture of themul-
tivalent trimeric ALX-0171 Nanobody. Further streamlining of
the typical Pichia pastoris fermentation process resulted in an
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ALX-0171 upstream process in which more than 7.5 g/liter ALX-
0171 was secreted in the fermentation broth. After clarification of
the broth, the downstream process consisted of capture, interme-
diate purification, and polish chromatography steps and was fol-
lowed by a final formulation step. A range of ALX-0171 concen-
trations was tested in combination with a series of buffers and
excipients to provide the highest stability after storage, nebuliza-
tion, freeze-thaw, etc. These formulation and (stressed) stability
studies resulted in the formulation of ALX-0171 as a stable nebu-
lizer solution.
Characteristics of ALX-0171 binding to RSV F protein. The
kinetics of Nb017 and ALX-0171 binding to the RSV F protein in
its prefusion conformationwas assessed by SPR analysis. The con-
formational integrity of the F protein was confirmed with the an-
tigenic siteØ-specific FabD25, which bound only to the prefusion
conformation, whereas the antigenic site I-specific Fab 2F did not
bind to the prefusion conformation, as expected. The binding
affinity of palivizumab was 0.88 nM on the prefusion conforma-
tion, which is in a range similar to that of previously reported data
(22, 32) (Table 1). Although Nanobody Nb017 was originally se-
lected for binding to the RSV F protein in its postfusion confor-
mation, as this was the only tool available at the time, both ALX-
0171 and Nb017 were shown to bind the prefusion conformation
of the F protein. The formatting of Nb017 into trimeric ALX-0171
increased the binding affinity by160-fold (KD, 0.113 nM) com-
pared to that of the monovalent Nb017 (KD, 17.88 nM) (Table 1).
Formatting to ALX-0171 greatly increased in vitro potency
against RSV-A and RSV-B.Microneutralization assays were used
to investigate whether trimeric formatting of Nb017 (ALX-0171)
would improve the neutralization capacity. The monovalent and
trivalent formats inhibited the replication of the RSV-A (Long)
and RSV-B (18537) strains in a dose-dependent manner (Fig. 1).
Formatting of the monovalent building block into a trivalent
compound greatly increased the potency by roughly 6,000-fold
against RSV-A Long and 10,000-fold against RSV-B 18537.
ALX-0171 was 126- and 6-fold more potent than palivizumab
against RSV-A Long and RSV-B 18537, respectively (Table 2).
This increased potency of ALX-0171 over the potencies of the
monovalent Nb017 and palivizumab was considerably more than
anticipated on the basis of affinity differences. Similarly, the con-
version of palivizumab Fab to full-length IgG resulted in an im-
proved potency of 200-fold with only a marginal 5-fold in-
crease in KD (22, 33).
ALX-0171 neutralizes a wide panel of clinical RSV isolates.
The neutralization capacity of ALX-0171 toward RSV clinical iso-
lates was tested. For this evaluation, 3 RSV-A strains isolated at
Queen’s University Belfast, Belfast, Northern Ireland, United
Kingdom, and 3 RSV-B strains isolated at the Baylor College of
Medicine, Houston, TX, were selected. The 50% virus neutraliza-
tion titers (as determined by endpoint dilution assays) are shown
in Table 2. ALX-0171 was 180-fold more potent than palivi-
zumab against the RSV-A clinical isolates tested (range, 180- to
409-fold) and12-foldmore potent than palivizumab against the
RSV-B clinical isolates tested (range, 11.5- to 647.5-fold), and this
potency difference was in the same range as that determined for
the prototypic RSV-A Long and RSV-B 18537 strains (177- and
17-fold, respectively) using the same assay.
To provide a more comprehensive understanding of the rela-
tive neutralization capacity of ALX-0171 and palivizumab against
a large panel of RSV clinical isolates, 61 RSV isolates, including the
RSV Tracy and RSV-B 18537 strains (see Table S1 in the supple-
mental material), were tested for inhibition by ALX-0171 and
palivizumab at a single concentration of 40 g/ml in a semiquan-
titative plaque reduction assay. This concentration represents the
mean 30-day trough serumconcentration of palivizumab after the
first intramuscular injection (32). ALX-0171 and palivizumab re-
duced the viral titers by 2 log10 for 97% and 85% of viruses tested,
respectively (Table 3). For RSV-A isolates, this proportion was
TABLE 1 Affinities of ALX-0171, Nb017, and palivizumab toward RSV prefusion F protein measured by SPR
Compound kon (M
1 s1 [106]) koff (s
1 [104]) KD (nM) Rmax (RU) 
2 (RU2)
Nb017 1.305 233.5 17.880 14.73 0.713
ALX-0171 4.091 4.604 0.113 24.30 0.46
Palivizumab 0.084 0.739 0.879 56.2 0.0947
Fab D25 0.488 0.331 0.068 51.78 0.158
Fab 2F 20
FIG 1 Microneutralization assay with ALX-0171, Nb017, and palivizumab. The capacities of ALX-0171, Nb017, and palivizumab to neutralize RSV-A Long (A)
and RSV-B 18537 (B) were tested. The results shown depict the means of triplicate values	 SEs. OD, optical density.
Detalle et al.
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100% with ALX-0171 and 84.4% with palivizumab (P 
 0.053),
and for RSV-B isolates, this proportionwas 93.1%with ALX-0171
and 86.2% with palivizumab (P
 0.67). These results are consis-
tent with published data demonstrating that palivizumab neutral-
ized 75/77 (97%) clinical isolates tested (32). Importantly, ALX-
0171 demonstrated a broad RSV strain neutralization capacity
that was at least as extensive as that of palivizumab when looking
at 2 log10 reductions.
Our data were the most striking when the complete suppres-
sion of RSV replication was compared between ALX-0171 and
palivizumab.When they were tested at equivalent concentrations,
ALX-0171 completely blocked replication in 87% of the viruses
tested, whereas palivizumab completely blocked replication in
18% (P 0.0001). This difference between ALX-0171 and palivi-
zumab, which is likely the consequence of the higher potency of
ALX-0171 (as shown in Table 2) and the lower molecular weight
of ALX-0171 compared with that of full-length MAbs (42.2 for
ALX-0171 versus 148 for palivizumab [32]), is indicative of a
lower neutralization threshold for ALX-0171 than for palivi-
zumab.
ALX-0171 binds to antigenic site II of F protein. To identify
the residues that are important for the binding of ALX-0171 to
RSV F protein, studies of the binding of monovalent Nb017 to
RSV-ALong escapemutants containing a single pointmutation in
antigenic site II or IV were performed (Fig. 2). These tested RSV
escape mutants, which are listed in Table 4, were previously re-
ported and selected withmonoclonal antibodies to these sites (11,
28, 29). The binding of Nb017 to antigenic site II, but not site IV,
mutants was significantly reduced (Table 4). In addition, binding
of ALX-0171 to the RSV F protein competed with that of palivi-
zumab, although only partially (Fig. 3 and data not shown). These
results provide further evidence that Nb017 and, consequently,
ALX-0171 target antigenic site II of the F protein and that its
epitope is close to or overlaps that of palivizumab.
ALX-0171 retains physicochemical properties following
nebulization. As the intended route of ALX-0171 administration
is by inhalation, it is important that ALX-0171 withstand the neb-
ulization process. An Akita2 Apixneb nebulizer was used to nebu-
lize ALX-0171, and the collected aerosol was characterized for
product stability by size-exclusion (SE) high-pressure liquid chro-
matography (HPLC) (to determine purity/impurity), reverse-
phase (RP)-HPLC (to determine purity), and ELISA (to determine
potency). These analytical methods were suitable for assessing high-
er-molecular-weight product-related variants (i.e., dimeric, trim-
eric, and higher-multimer forms of ALX-0171), protein fragmen-
tation, and potential changes in potency. During product
development, no physicochemical changes were observed by RP-
HPLC analysis after nebulization. SE-HPLC analysis showed a
small increase in higher-molecular-weight species after nebuliza-
tion. The formation of higher-molecular-weight species by nebu-
lization was monitored during long-term stability studies and re-
mained minimal, not exceeding 2% after nebulization.
TABLE 2 Neutralization of RSV prototypic and clinical isolatesa
RSV strain
IC50 VN50
Mean	 SD IC50 (nM) Fold
difference
Mean	 SD VN50 (nM) Fold
differenceALX-0171 Palivizumab ALX-0171 Palivizumab
RSV-A
Long 0.1	 0.07 (n
 3) 12.6	 5.4 (n
 3) 126 0.03	 0.02 (n
 3) 5.2	 0.8 (n
 3) 177
BT2ab 0.011	 0.006 (n
 3) 4.06	 1.39 (n
 3) 380
BT3ab 0.01	 0.005 (n
 3) 3.95	 0.61 (n
 3) 409
BT4ab 0.006	 0.006 (n
 3) 1.14	 0.91 (n
 3) 180
RSV-B
18537 0.4	 0.2 (n
 20) 2.4	 1.2 (n
 5) 6 0.42	 0.66 (n
 6) 7.17	 5.52 (n
 6) 17
B-TX-60567b 0.24	 0.22 (n
 3) 2.8	 0.8 (n
 3) 11.5
B-TX-61406b 0.028	 0.026 (n
 3) 2.0	 1.1 (n
 3) 72.3
B-TX-79233b 0.003	 0.001 (n
 3) 1.7	 2.2 (n
 3) 647.5
a IC50, 50% inhibitory concentration; VN50, 50% virus neutralization titer; n, number of isolates.
b These viruses have been reported previously (30, 31).
TABLE 3 Comparative inhibition of in vitro replication of a panel of RSV clinical isolates by palivizumab and ALX-0171 by100-fold or
completely
RSV group GMTa (log10)
No. of isolates with a100-fold
reduction/total no. of isolates
tested (%)
P valueb
No. of isolates with complete
inhibition/total no. of isolates
tested (%)c
P valuePalivizumab ALX-0171 Palivizumab ALX-0171
RSV-A 4.9	 0.4 27/32 (84.4) 32/32 (100) 0.053 0/32 (0) 30/32 (93.8) 0.0001
RSV-B 4.7	 0.4 25/29 (86.2) 27/29 (93.1) 0.67 11/29 (37.9) 23/29 (79.3) 0.003
Total 52/61 (85.2) 59/61 (96.7) 0.054 11/61 (18) 53/61 (86.9) 0.0001
a GMT, geometric mean titer of buffer controls.
b Differences between groups were analyzed using Fisher’s exact test for comparison of proportions. Significance was defined at a P value of0.05.
c Complete virus inhibition was defined as no detectable virus plaques. The limit of virus detection in the plaque reduction neutralization assay was 5 PFU/ml.
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Furthermore, no effect of nebulization on ALX-0171 potency was
observed by ELISA analysis (see Table S2 in the supplemental
material).
Local delivery of ALX-0171 to cotton rats reduces the RSV
load in the nose and lung.Cotton rats were used to evaluate the in
vivo efficacy of ALX-0171 against RSV. Different doses of ALX-
0171 were administered via the intranasal route on different days
after RSV Tracy challenge either once (day 2 or day 3) or twice
(day 2 and day 3) or by nebulization 1 h before RSV Tracy chal-
lenge (Table 5). On day 4 the cotton rats were sacrificed and the
viral titers in both the nose and lung were determined.
Intranasal administration of ALX-0171 on day 2, day 3, or days
2 and 3 after RSV challenge resulted in significant viral load reduc-
tions in the lungs ranging from50-fold (1.66 log10) for the low-
est dose tested (1 mg/kg) (P 0.0001) to2,000-fold (3.3 log10)
for the highest dose tested (68 mg/kg) (P  0.0001). Nasal RSV
titers were also significantly reduced for all doses and schedules
tested (P 0.0001), except for the day 2 treatment at 4mg/kg (P

0.7).
As the intended route of delivery of ALX-0171 is by nebuliza-
tion, we performed a proof-of-concept experiment to confirm
that nebulization did not affect the antiviral activity of ALX-0171.
For this experiment, prophylactic delivery of ALX-0171 via nebu-
lizationwas chosen as themost straightforward approach. In total,
4 groups of 6 cotton rats received estimated delivered doses of 0.3
mg/kg, 0.8 mg/kg, and 2 mg/kg 1 h before RSV Tracy challenge
(Table 5). A dose-dependent reduction in viral titers was seen in
the nose, which was significant for the two higher doses (P
 0.01
and 0.006 for doses of 0.8 mg/kg and 2 mg/kg, respectively). Fur-
thermore, RSV replication was almost completely blocked in the
lungs, even at the lowest dose tested (3.67 log10 reduction, P
0.0001).
DISCUSSION
ALX-0171 is a novel therapeutic biologic in development for the
treatment of RSV infections in infants. ALX-0171 is a trimeric
Nanobody that binds an epitope in antigenic site II of RSV F
protein with subnanomolar affinity. This epitope partially over-
laps the palivizumab epitope.
The formatting of the monovalent Nb017 into the trivalent
Nanobody ALX-0171 increased the potency of neutralization
(6,000-fold) of both RSV-A and RSV-B strains. Although for-
matting clearly increased the binding affinity for the biologically
relevant prefusion conformation of the F protein (160-fold), it
does not fully explain the observed large increase in the virus neu-
tralization capacity of ALX-0171. Our results are consistent with
those of a previous report demonstrating that a bivalent Nano-
body construct specific for F-protein antigenic site II had a 4,000-
fold improved neutralization capacity compared to that of the
monovalent construct against RSV-A Long (22). Likewise, the dif-
ference in potency between palivizumab Fab and the full-length
antibody is 100-fold, while there is only a minimal improvement
FIG 2 Crystal structure representation of the F protein in its prefusion con-
formation. Ribbon representation of one prefusion F-protein protomer is
shown in red, and the other twoprotomers are shown in surface representation
in blue and green. The residues listed are those that were mutated in the tested
RSV escapemutants and are shown in yellow. The figurewas prepared by using
ICM Molsoft (46) and was derived from the sequence with PDB accession
number 4JHW (26).
TABLE 4 Binding reactivity of Nb017 to membrane extracts of cells
infected with distinct RSV-A Long escape mutantsa
RSV
mutant
Amino acid
substitution(s)
Antigenic
site
% Nb017
bindingb
R47F/4 N262Y II 1.4	 1.6
R47F/7 N268I II 61.1	 17.2
RAK13/4 N216D/N262Y II 0.6	 0.8
R7C2/11 K272T II 19.5	 16.8
R7C2/1 K272E II 0.9	 1.1
R7.936/1 V447A IV 119.9 37.3
R7.936/4 K433T IV 122.3 40.5
R7.936/6 I432T IV 106.5 15.9
R9.432/1 S436F IV 121.4 20.0
RRA3 N262Y/R429S II and IV 1.6	 3.2
a Absorbance results were normalized to those for a reference Nanobody recognizing
antigenic site I (191C7) with preserved binding to all depicted mutants to account for
the difference in F-protein expression. Nb017 was used at 0.2 g/ml.
b Data represent the percent binding to that of the reference RSV-A Long wild-type
strain	 standard deviation. Shading and boldface indicate where the binding of Nb017
was75%, shading indicates where the binding of Nb017 was 25 to 75%, and no
shading indicates where the binding of Nb017 was25%.
FIG 3 Results of competitive-binding ELISAs. The inhibition concentration-
response curves obtained when biotinylated ALX-0171 was incubated with
increasing concentrations of either unlabeled ALX-0171 or palivizumab are
shown. The results shown depict the means of triplicate values	 SEs.
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in the KD (33). However, the basis of this observation is not yet
understood, and the precise mechanisms involved remain under
investigation.
Like palivizumab, Nanobodies Nb017 and ALX-0171 bind to
both the postfusion and prefusion conformation of the F protein
and, as a result, likely inhibit the conformational changes related
to F-protein activation, as suggested for other Nanobodies and
monoclonal antibodies specific for antigenic site II (21, 34–36).
This hypothesis is supported by a model of the RSV F-protein
prefusion structure, in which the residues of antigenic site II are
proximal to sequences that form the central -helical coil of the
6-helix bundles in the postfusion conformation of the F protein
(35).
Importantly, the capacity of ALX-0171 to neutralize recent
clinical isolates or prototypic strains greatly surpassed that of
palivizumab in terms of both plaque reductions and the complete
block of RSV infection. This increased inhibition efficiency was
consistent with previous reports, in which the virus- and cell-cell
fusion-inhibiting capacity of a bivalent Nanobody targeting F-
protein antigenic site II was compared to that of palivizumab (21,
22). There are several possible explanations for this difference in
neutralization capacity: (i) the smaller size of ALX-0171 and its
extended complementarity-determining region loops may en-
hance the accessibility to F-protein antigenic site II (37, 38), (ii)
the GS linker is likely more flexible than the hinge of a full-length
antibody, and thus, ALX-0171 would be able to access its binding
site more readily, and (iii) the trivalency of ALX-0171 may allow
additional binding modes, such as simultaneous binding of three
independent F-protein trimers or simultaneous binding of the
three subunits within a single F-protein trimer (20, 21), as the
length of the GS linkers was specifically designed to allow such
interactions. Further crystallography studies are needed to eluci-
date the mechanisms involved in this increased neutralization ca-
pacity of ALX-0171.
In vivo, ALX-0171 was shown to be highly efficient at reducing
and/or blocking RSV replication in the lung and nose, similar to
what was reported for motavizumab, an affinity-matured version
of palivizumab (39, 40), whereas no effect on viral load in the nose
was demonstrated for palivizumab at doses of15mg/kg (40, 41).
There remains the possibility that the residual ALX-0171 present
in the wash fluid interfered in the plaque assay. Nonetheless, de-
spite this caveat, we believe that it remains the most valid assess-
ment, as it reflects the fact either that less virus is present or that
any virus still present is effectively neutralized. Importantly, as
ALX-0171 is devoid of an Fc, its in vivo efficacy likely relies entirely
on direct antiviral activity, in contrast to what has been reported
for palivizumab (42). In addition and in contrast to the route of
delivery of palivizumab and motavizumab, which were adminis-
tered systemically in therapeutic trials in infants and demon-
strated conflicting effects on nasal/tracheal viral loads (39, 41, 43),
ALX-0171 is delivered straight to the site of infection. Direct ad-
ministration to the airways is likely to provide faster and more
robust antiviral activity in the respiratory tract, which may be
critical for the treatment of an acute disease like RSV infection.
Indeed, the therapeutic effect of topical administration of purified
human immunoglobulins, screened for high RSV neutralization
TABLE 5 Reduction in RSV replication in cotton ratsa
Expt no., route of
delivery
ALX-0171
dose delivered
(mg/kg)
Treatment
regimen
Nasal titer Lung titer
Mean log10
total no. of
PFU (	SD)
Log10
reduction
vs buffer
Mean log10 no.
of PFU/g lung
(	SD)
Log10
reduction
vs buffer
Expt 1, intranasal Buffer Days2 and3 4.78 (0.40) 4.94 (0.13)
1 Days2 and3 3.46 (0.56) 1.32* 3.28 (0.40) 1.66*
2 Days2 and3 3.06 (0.75) 1.72* 3.14 (0.53) 1.81*
4 Days2 and3 2.53 (0.88) 2.26* 3.18 (0.43) 1.76*
21 Days2 and3 1.68 (0.28) 3.10* 2.05 (0.66) 2.89*
Expt 2, intranasal Buffer Days2 and3 4.84 (0.15) 5.19 (0.24)
4 Days2 and3 2.00 (0.72) 2.84* 2.04 (0.47) 3.15*
19 Days2 and3 1.73 (0.21) 3.31* 2.55 (1.13) 2.64*
68 Days2 and3 1.54 (0.59) 3.30* 1.88 (0.50) 3.30*
Expt 3, intranasal Buffer Days2 and3 4.81 (0.36) 4.88 (0.34)
4 Day2 4.53 (0.87) 0.28 2.88 (0.89) 2.00*
4 Day 3 1.84 (0.38) 2.97* 2.10 (0.22) 2.78*
5 Days2 and3 1.74 (0.30) 3.07* 2.72 (1.12) 2.16*
Expt 4, nebulization Bufferb Hour1 5.04 (0.25) 5.05 (0.22)
0.3b Hour1 3.97 (0.62) 1.07 1.26 (0.34) 3.79*
0.8b Hour1 3.02 (1.46) 2.02* 1.38 (0.43) 3.67*
2b Hour1 2.87 (1.42) 2.18* 1.09 (0.05) 3.96*
a Cotton rats (6 to 8 rats per group) were challenged with 1.41 105 to 3.4 105 PFU of RSV Tracy (intranasally, 100 l) on day 0. The animals received ALX-0171 at the
indicated times either by intranasal administration or by nebulization. Viral titers and viral RNA loads in both the lung and nose were assessed on day 4 postinfection. *, P 0.05
versus buffer control. P values were determined by ANOVA with a follow-up Dunnett’s pairwise comparison test.
b The delivered dose was estimated. The estimated delivered dose was defined as the estimated dose that is inhalable by the cotton rats and was calculated using the following
formula: delivered dose (in micrograms per kilogram of body weight)
 (aerosol concentration [in micrograms per liter]) (minute volume [in liters-minute per kilogram])
(treatment time [in minutes]) percentage of particles of5 m (respirable fraction), where the minute volume was estimated to be 0.7 liter-min/kg (47) and the respirable
fraction was estimated to be 80% on the basis of the characteristics of the nebulizer.
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activity, resulting in a decrease in viral loads in cotton rats was
shown to be 160 times greater than that by administration by the
parenteral route (44). In addition to the greater effectiveness of the
ALX-0171 administration route, the neutralization threshold of
ALX-0171 (i.e., the expected lung concentration needed to exert
the full antiviral effect) is also anticipated to be lower than that of
palivizumab. This is particularly important in a clinical setting
where the administered dose is a limiting factor.
In summary, ALX-0171 represents a novel, highly potent anti-
viral with broad specificity toward a large panel of RSV clinical
isolates and may have significant potential for therapeutic use.
Furthermore, direct delivery of ALX-0171 to the airways/lungs by
nebulization proved an effective mode of drug delivery, as even
the lowest dose of only 1 mg/kg delivered intranasally still showed
antiviral efficacy. As nebulization has been shown to result in fast
and efficient drug delivery to the principal site of RSV infection
(45), i.e., the upper and lower respiratory tract, this mode of drug
delivery may provide major therapeutic advantages for ALX-0171
in treating RSV-infected patients.
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